Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Enlivex Therapeutics (NASDAQ:ENLV) from a "sell" to a "hold," and MarketBeat shows a consensus rating of Hold with a consensus price target of $16.50.
• HC Wainwright raised its price target from $13 to $20 and rates the stock a "buy," while other analysts remain mixed (one Buy, one Hold, one Sell), reflecting divergent views on the company's outlook.
• Shares opened at about $0.89 (52‑week range $0.66–$2.10) with a market cap of ~$211.3 million and a negative P/E, and institutional ownership is very low at approximately 1.02%.

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enlivex Therapeutics has a consensus rating of "Hold" and a consensus price target of $16.50.

Enlivex Therapeutics Stock Down 1.8%

Shares of NASDAQ:ENLV opened at $0.89 on Friday. Enlivex Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.10. The firm has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.00. The company has a market cap of $211.27 million, a PE ratio of -1.62 and a beta of 1.68.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd lifted its stake in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock worth $43,000 after acquiring an additional 19,132 shares during the period. Virtu Financial LLC acquired a new stake in shares of Enlivex Therapeutics in the 4th quarter worth approximately $33,000. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company's stock worth $52,000 after acquiring an additional 52,553 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics in the 3rd quarter worth approximately $57,000. Finally, Invesco Ltd. acquired a new stake in shares of Enlivex Therapeutics in the 4th quarter worth approximately $43,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.